Market Research Blog – Page 382 – New Product Development

Gum Rosin Market: Driving Demand in Adhesives and Coatings Amid Sustainability Trends

The global gum rosin market is projected to attain a value of USD 1,106.3 million in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 6% during the assessment period, reaching approximately USD 1,987 million by 2034. This growth is driven by increasing demand across various industries, including adhesives, printing inks, and rubber, where gum rosin’s versatile properties as a natural resin are highly valued. As industries continue to seek sustainable and natural raw materials, the market for gum rosin is likely to witness robust expansion over the next decade.

Gum rosin is a kind of solid resin made from pine chemicals that are sourced from pine trees and various other plants. Also known as colophony, gum rosin is made by heating the fresh liquid resin to vaporize the volatile liquid terpene compounds. It is composed of a mixture of pimaric-type and abietic-type acids with a low amount of neutral compounds. Gum rosin Color’s ranging from yellow to black and has a semi-transparent appearance.

The market for gum rosin is positively influenced by the increasing application of the product in adhesives. An upsurge in preference for natural additives across various industry verticals. Gum rosin also finds application in the automotive and construction sectors as it is used in the paints and coatings used in these industries. Other applications of gum rosin include its usage as a glazing agent in chewing gum and medicines, as a dispersant and as emulsification in the synthetic rubber industry will spur the demand for gum rosin in the global market. Again, the high friction-enhancing properties of gum rosin will further swell up the demand for gum rosin in the upcoming years.

Gum rosin contains excellent physical and chemical properties which promote its usage in the manufacturing of adhesives, printing inks, paper sizing agents, solders and fluxes, surface coatings, insulating materials, synthetic rubber, chewing gums, and soaps and detergents. Gum rosin can also be used on bows of violins and other string instruments, dancing shoes, floors, and stages to prevent slipping. All of these considerations, along with others, propel the gum rosin market forward in the international space.

Key Takeaways:

China dominates the global gum rosin market, primarily due to its strong export capacity and ability to maintain lower-than-average prices.
The gum rosin market in United States will register a CAGR of 5.4% and create an absolute dollar opportunity by 2034.
By product type, the WW-type segment will account for 31.5% of the market share in 2024 due to its extensive usage in paper sizing for maintaining textures and colors.
In terms of application, the adhesive segment will continue to dominate the market and is projected to hold a leading value share of 30.2% in 2024.

Gain Detailed Understanding by Reviewing the Complete Report!

Leading Gum Rosin Market Players

Forestar Chemical Co., Ltd
Wuzhou Sun Shine Forestry & Chemicals Co., Ltd
Megara Resins
Wuzhou Pine Chemicals Ltd
Merck Group
Resin Chemicals Co., Ltd
Midhills
Eastman Chemical
Guilin Songquan Forest Chemical Co., Ltd
Punjab Rosin and Chemicals Works

Key Segments of Market Report

By Product Type:

In terms of product type, the industry is segregated into WW-type, WG-type, N-type, X-type, and others.

By Application:

Paper, paints and coatings, soap, printing ink, adhesives, and rubber are a few key applications.

By Region:

The industry is spread across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries. Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Rare Earth Metals Market: Rising Demand for Neodymium Magnets Driven by the Global EV Boom

The Rare Earth Metals Market is expected to witness robust growth over the forecast period, with a projected market size increase from USD 6.2 billion in 2024 to USD 16.1 billion by 2034, at a CAGR of 10.1%. The growing demand for rare earth metals is largely fueled by their essential role in modern technologies such as electric vehicles (EVs), renewable energy systems, and advanced electronics.

Rare earth metals, which include elements like neodymium, dysprosium, and terbium, are critical components in the production of high-efficiency magnets, batteries, and catalysts. The transition to green energy solutions and the rise of electric mobility have significantly increased the need for these materials. Moreover, rare earth metals are integral in the production of wind turbines, fuel cells, and other sustainable energy applications, driving their global demand.

Asia-Pacific, particularly China, continues to dominate the rare earth metals market due to its vast reserves and established supply chain. However, the demand in North America and Europe is also accelerating, driven by advancements in renewable energy and EV infrastructure. With increasing government policies supporting clean energy transitions, the rare earth metals market is expected to see a sustained upward trajectory.

Key Takeaways from Market Study:

The Rare Earth Metals Market is projected to grow from USD 6.2 billion in 2024 to USD 16.1 billion by 2034, at a CAGR of 10.1%.
Electric vehicle and renewable energy sectors are major drivers of market growth.
Increasing investments in rare earth metal recycling offer new growth avenues.
Asia-Pacific remains the dominant region, with China as the primary global supplier of rare earth metals.

Unlock Comprehensive Insights by Reading the Full Report Now!

Key Manufacturers in the Rare earth metals Market

Baotou Rare Earth
China Minmetal Rare Earth
Avalon Advanced Materials
IREL
Metall Rare Earth Limited
Arafura Resources
Canada Rare Earth Corporation
Lynas Corporation
Northern Minerals
Greenland Minerals Limited
Sigma-Aldrich
GanZhou QianDong Rare Earth Group Co. Ltd.
Shenghe Resources Holdings Co., Ltd.
Geomega Resources Inc
Solvay (Belgium), Hitachi Metals Ltd.

Key Segments of Market Report

By Metal Type:

Metal type is segmented into in Neodymium, Yttrium, Dysprosium, Terbium, Europium, Cerium and Lanthanum.

By Application:

Catalysts, Permanent Magnets, Metallurgy and Alloys, Polishing, Glass, Phosphors, Ceramics and others are the applications.

By Region:

The industry is spread across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia, and the Middle East and Africa.

About Future Market Insights (FMI)

Contact Us:

Global Renewable Methanol Market Growing at a 6.6% CAGR Driven by Sustainability Trends and Demand for Bio-based Chemicals

The global renewable methanol market is expected to experience significant growth, with a projected compound annual growth rate (CAGR) of 6.6% during the forecast period. As demand for sustainable and eco-friendly energy sources intensifies, renewable methanol is gaining traction as a clean alternative to conventional fossil-based methanol. This growth is driven by increasing adoption in various applications such as transportation, chemicals, and energy storage, where renewable methanol serves as a vital building block for reducing carbon emissions. By 2033, the market is anticipated to surpass USD 398.1 million, reflecting the growing shift toward decarbonizing industrial processes and contributing to global sustainability goals.

As it is used in the chemical sector to make acetic acid, formaldehyde, and plastics, there is expected to be an increase in demand for renewable methanol throughout the projection period. To produce polyethylene and polypropylene, much more biomethanol is now being used. Moreover, the main applications of biomethanol are as fuel for industrial boilers, vehicles, ships, and kitchen appliances.

The key reasons behind the market expansion include decreasing or eliminating CO2 emissions to prevent climate change drastically and the increased emphasis on limiting the average global temperature rise to no more than 1.5°C. This suggests that emissions throughout the economy are net zero by the middle of the century.

In some industries with few choices for carbon emission reduction, biomethanol has been more effective as a feedstock in the chemical industry or as a fuel for land or marine transportation.

Low petrol costs are also affecting the use of renewable methanol. Due to weak domestic and global demand, several EU, Brazil, and United States production facilities have cut their output. As a result of the decreased demand, renewable methanol stocks are predicted to rise across several markets, driving down prices and jeopardizing profitability.

Key Takeaways

By 2033, the renewable methanol market in the United Kingdom is likely to expand, with a CAGR of 5.8%.
In 2023, the United States is expected to develop the renewable methanol business with a share of 22.4%.
The renewable methanol market size grew considerably to US$ 201.1 million in 2022.
The renewable methanol industry expanded at a CAGR of 6.8% from 2018 to 2022.
By 2033, China’s renewable methanol market is projected to have a CAGR of 6.9%.
By 2033, India’s renewable methanol industry is projected to expand with a CAGR of 7.3%.
Japan’s renewable methanol sector is likely to grow significantly, with a 10.2% share in 2023.
Australia’s renewable methanol is expected to develop with a share of 3.1% in 2023.
Germany’s renewable methanol business is expected to grow, with a share of 15.4% in 2023.
In 2023, based on a primary source, the biomass feedstock segment is expected to dominate the market, with a share of 42%.
In 2023, based on application, the formaldehyde segment is expected to dominate the market, with a share of 25%.

Navigate the Renewable Methanol Market Landscape with Expert Findings in the Complete Report!

Top Key Players in the Renewable Methanol Market

Methanex Corporation
Carbon Recycling International
BioMCN
Enerkem
Chemrec Inc.
VarmlandsMethanol
Alberta Pacific
New Hope Energy
Trans World Energy
Proman
ENI
BASF SE

Regional Analysis:

United States (22.4% market share in 2023): The U.S. is a major consumer of renewable methanol, driven by strict government regulations aimed at reducing carbon footprints and increasing the use of methanol in fuel and products. This is further supported by the robust sales of electric vehicles, positioning the U.S. to maintain a significant market share.
India (7.3% CAGR from 2023 to 2033): India’s renewable methanol market is expanding due to stringent vehicle emission regulations (BS – III, BS – IV, BS – VI) and the mandatory use of methanol in fuel blending. Additionally, the growing electric vehicle sector, supported by government incentives and subsidies, further boosts the market, contributing to a strong growth trajectory.
Japan (15.4% market share in 2023): Japan continues to be a key player in the renewable methanol market, with a focus on reducing emissions and incorporating renewable methanol into energy solutions.
Germany (10.2% market share in 2023): Germany’s strong regulatory environment and commitment to green energy solutions position it as a significant market for renewable methanol, supporting its transition to cleaner fuels.
Australia (3.1% market share in 2023): Australia’s renewable methanol market is driven by growing sustainability initiatives and government support for clean energy technologies.

About Future Market Insights (FMI)

Contact Us:

Global Brain Metastasis Therapeutics Market to Reach USD 6,915.2 million by 2033, Advancing at a CAGR of 7.8%

The global brain metastasis therapeutics market is poised for significant growth, with an anticipated compound annual growth rate (CAGR) of 7.8% over the forecast period. As of 2023, the market is valued at USD 3,269.8 million and is projected to expand to USD 6,915.2 million by 2033.

The sweeping rate of cancer incidences is pushing the probability of brain metastasis. Thus, contributing to the brain metastasis therapeutics industry growth. To bring efficiency to diagnostic technology, companies are enhancing their diagnostic techniques like positron emission tomography (PET), magnetic resonance imaging (MRI), and molecular profiling. Due to their precise diagnosis and early detection of brain metastasis, healthcare providers can timely initiate treatment.

As patients suffering from brain metastasis appear to multiply, treatment modalities exhibit constant evolution. Some of these modalities include immunotherapy, stereotactic radiosurgery, and targeted therapies. They significantly enhance patient outcomes for brain metastasis. For more effective patient outcomes, end users have started giving options for personalized treatment plans.

Increasing healthcare budgets and better access to medical facilities in developing economies are expected to attract top vendors for possible growth.

Pharmaceutical firms, academic centers, and research institutes are collaborating to develop new treatment approaches and expedite the advancement of brain metastasis therapeutics. Concerted efforts are expected to promote knowledge sharing, research funding, and access to resources, and propel market growth.

Top Highlights from the FMI’s Analysis of the Brain Metastasis Therapeutics Market:

North America contributed a gigantic share of 35% in the historical period. The region is expected to tread on the same trend over the forecast period. Increasing clinical trials and novel drug development for brain metastasis are expected to enhance the treatment options and drive positive outcomes for patients.
Within North America, the United States market is expected to record a 30.9% share. The country is expected to observe prime time, as patients across the globe are seeking superior quality medical treatment. Additionally, manufacturers are crowding the country to gain from the said trend.
Europe is another key region for brain metastasis therapeutics, sharing 24.5% of the global market. Due to government support, heightened technological innovations, and increasing cases of brain metastasis, enterprises residing or entering the region are expected to observe several growth prospects.
Germany’s stake in the market was 5.7% in 2022. The efficient healthcare system in the country is expected to support the country’s growth.
Due to the large pool of geriatric people susceptible to brain metastasis, Japan is expected to offer lucrative opportunities for manufacturers.
China is expected to thrive in the upcoming years, as FMI anticipates that the country is going to witness a 9.8% CAGR from 2023 to 2033. Enterprises can most benefit from expanding their business into developing countries to meet the increasing demand for brain metastasis therapeutics.
Australia is yet another country observing a high growth of 7.8% over the forecast period. The country offers significant opportunities for businesses to foray into the market.
For treatment, patients mostly opt for radiation therapy due to its effective results. In 2022, the radiation therapy segment accounted for 32.1% market share.
Largely, cancer hospitals deploy brain metastasis therapeutics to treat the related disorder. In 2022, the cancer hospitals segment accounted for 44.9% market share.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!

Latest Ongoings in the Market: Key Players in the News

Zion Pharma Limited, a Chinese firm known for its biotechnology, announced its agreement with Roche to innovate and then commercialize oral HER2 tyrosine kinase inhibitor, which is a blood-brain barrier penetrant. The compound can avoid the onset of brain metastases in HER2-positive metastatic breast cancer patients.
In June 2023, NeOnc Technologies Holdings, Inc. announced that it had received a green light from FDA to advance with Phase 1/2 Trials of NEO212. These trials will address primary brain tumors and brain metastasis, along with offering standard-of-care therapy. The main aim of this trial is to evaluate the preliminary efficacy and safety of NEO212.
A phase 2 clinical trial of pembrolizumab displays positive results, with data reflecting 42% of metastatic brain cancer patients benefitting from the treatment. However, the research suggests that therapy’s benefits must be weighed against toxicity risks.

Key Companies Profiled:

Bayer AG
Pfizer Inc.
Sanofi
F. Hoffmann-La Roche Ltd.
Eli Lilly & Company
Novartis AG
GlaxoSmithKline
Merck & Co. Inc.
AstraZeneca
AngioChem Inc.

Key Segments Profiled in the Brain Metastasis Therapeutics Market Survey

By Treatment Type:

Radiation Therapy
Chemotherapy
Targeted Therapy
Anticonvulsants
Corticosteroids

By End Use:

Cancer Hospitals
Clinics
Cancer Research Centers

By Region:

North America
Latin America
Asia Pacific
Middle East and Africa
Europe

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global X-ray Photoelectron Spectroscopy Market Set to Experience Steady Growth USD 1,078.4 Million by 2034 | FMI

The global X-ray photoelectron spectroscopy market is poised for steady growth, with sales expected to reach USD 850.7 million in 2024 and project a rise to USD 1,078.4 million by 2034. This growth reflects a compound annual growth rate (CAGR) of 2.4% during the forecast period from 2024 to 2034, marking a slight increase from USD 830.8 million in 2023. Year-over-year (Y-o-Y) growth is forecasted at 2.5% in 2024.

XPS: A Game-Changer in Surface Analysis Across Industries

XPS is an advanced surface-sensitive analytical technique that has transformed the way industries study material surface composition and chemical states. By utilizing X-rays to trigger core electron emissions, XPS enables researchers to unlock essential insights into the properties of materials like thin films, coatings, catalysts, and semiconductors. This versatile technique finds wide-ranging applications across material science, chemistry, and electronics, but its most impactful role lies in the healthcare sector.

Healthcare Sector Driving XPS Adoption

The healthcare sector is increasingly harnessing the power of XPS, particularly in the areas of biomaterial analysis, medical implant development, and pharmaceutical formulations. XPS ensures the biocompatibility of medical devices, including stents, prosthetics, and dental implants, by providing a thorough understanding of material properties and minimizing adverse reactions in patients. This growing emphasis on biocompatibility testing is driving the adoption of XPS technologies for evaluating medical devices and conducting complex pharmaceutical research.

As the demand for safer, more effective medical solutions rises, the role of XPS in healthcare will continue to expand, contributing to the steady market growth expected in the coming years.

The market’s upward trajectory is a testament to the increasing reliance on XPS for critical applications that ensure the safety, effectiveness, and biocompatibility of medical technologies. With steady growth anticipated, the X-ray photoelectron spectroscopy market is solidifying its position as an indispensable tool across industries, particularly in healthcare.

Key Growth Drivers:

Technological Advancements: Continuous innovation in XPS technology enhances precision and expands its capabilities, making it indispensable for surface interaction studies.
Research and Development Investment: Rising investments in material science research accelerate the discovery of novel materials, boosting demand for XPS analysis.
Diverse Applications: XPS’s versatility extends beyond healthcare to sectors like electronics, coatings, and catalysts, fueling its global adoption.

Future Outlook:

The increasing need for advanced material analysis, coupled with growing applications in critical industries, positions XPS as a cornerstone of surface science. With robust growth anticipated over the next decade, stakeholders across healthcare, material science, and industrial research are poised to benefit from this transformative technology.

Key Takeaways: Market Growth Insights (2024-2034)

Market Overview:
- The market demonstrated a historical size of USD 830.8 million in 2023 and is estimated to grow to USD 850.7 million in 2024.
- By 2034, the market is projected to reach USD 1,078.4 million, reflecting a steady CAGR of 2.4% from 2024 to 2034.
Regional Performance Highlights:
- China: Leads in growth with a projected 4% CAGR over the forecast period.
- India: Poised for significant expansion with a 7% CAGR, the highest among evaluated countries.
- South Korea: Anticipates a robust growth trajectory with a 9% CAGR.
- UK: Expected to exhibit moderate growth at a 9% CAGR.
- Japan: Projected to grow at a 0% CAGR, demonstrating stable market performance.
- Italy & Australia: Both forecasted to maintain a 1% CAGR, showcasing steady market contributions.

“The X-ray Photoelectron Spectroscopy market is experiencing steady growth, propelled by advancements in analytical techniques and the need for precise surface material analysis. As industries increasingly prioritize innovation and quality, XPS is emerging as an indispensable tool for research, development, and production processes. Its applications in cutting-edge fields like semiconductors and coatings will further cement its role as a critical technology in modern science.” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!

Competitive Landscape:

The X-ray photoelectron spectroscopy (XPS) industry is witnessing significant investments in research and development. Leading companies are prioritizing the launch of advanced systems designed to streamline and enhance the R&D process. Additionally, these key players are actively pursuing strategic partnerships to strengthen their product portfolios and expand their global market footprint.

Recent Developments in the X-ray Photoelectron Spectroscopy Market:

September 2023: Esko showcased the CDI Crystal XPS 4835 and AVT Helios System at Labelexpo Europe 2023. This strategic participation aimed to broaden its customer base and reinforce its position in the market.
July 2022: ULVAC-PHI introduced the PHI Genesis, a multifunctional and automated scanning X-ray photoelectron spectrometer. This innovative product integrates PHI’s advanced scanning XPS technologies for seamless and user-friendly operation.

Key Players of X-ray Photoelectron Spectroscopy Industry:

ESKO
Evans Analytical Group
Intertek Group plc
JEOL Group
Kratos Analytical
Thermo Fisher Scientific
Scienta Omicron
SPECS GmbH
Lucideon

Key Segments of X-ray Photoelectron Spectroscopy Industry:

By Usage Type:

In terms of Usage, the industry is divided into element detection, contamination detection, density estimation and empirical formula determination

By Application:

In terms of application, the industry is divided into healthcare, semiconductors, electronics, aerospace, automotive and others

By Analysis:

The industry is classified by analysis as forensic analysis, contamination analysis, corrosion chemistry analysis and others

By Region:

Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa (MEA) have been covered in the report.

About Future Market Insights (FMI)

Contact Us:

Strong Growth Projected for Vascular Dementia Treatment Market, Expected to Reach USD 8.99 Billion by 2033

The vascular dementia treatment market is poised for significant growth, with an estimated market value of USD 5.64 billion in FY 2023, marking a year-on-year increase of over 5%. This surge in demand highlights the growing awareness and need for effective treatments for vascular dementia, a condition that affects millions of individuals worldwide.

Over the forecast period from 2023 to 2033, the market is projected to expand at a robust compound annual growth rate (CAGR) of 4.77%. By FY 2033, the industry is expected to reach a market value of USD 8.99 billion, driven by continued advancements in medical research, increased healthcare access, and an aging global population.

The rise in vascular dementia cases, often linked to conditions such as stroke and cardiovascular disease, is contributing to the growing demand for targeted treatments. As healthcare providers and pharmaceutical companies continue to innovate, the market is anticipated to witness increased investment in both treatment options and early diagnosis technologies.

With the continuous development of new therapies, along with increased healthcare awareness and education, the vascular dementia treatment market is positioned for sustainable growth, offering hope to those affected by this debilitating condition.

Key Takeaways from the Market Study:

Market share of individual therapies with the current and forecasted 7 million market size from 2019-2032.
Decline in thinking skills, caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients.
Prevention of treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors, with prevention in the management of stroke, by early diagnosis and appropriate treatment of acute stroke
No cure for the condition or a way to reverse the damage already happened. But treatment can help prevent further damage to the brain in people with vascular dementia and may slow down its progression.
North America is expected to occupy a major share of the overall dementia drugs market during the forecasted period, followed by Asia where Malaysia has shown that the percentage of the population aged 65 years and over (old age) increased from 6.7% in 2019 to 7.0% in 2020.

“With substance abuse becoming an area of major concern, healthcare providers are looking to collaborate with various entities, including governmental bodies, to push for legalization, as well as develop novel treatment drugs, which will provide ample opportunities for companies to develop key drugs,” remarks an analyst at FMI.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!

Competitive Landscape:

The publisher performs competitive and market Intelligence analysis of the Vascular Dementia (VaD) market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

In April 2022- NovaMedica developed and registered an innovative combination of Donepezil and Memantine molecules, the primary therapies for dementia. The drug is registered under the name MIOREOL. This is one of the combinations in the Russian market and the markets of the Eurasian Economic Union members and Europe.
In March 2022- Corium, Inc. received United States FDA approval for ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia.

More Valuable Insights Available:

Future Market Insights offers an unbiased analysis of the vascular dementia treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.

Some of the prominent players are:

Charsire Biotechnology Corp
ProNeurogen Therapeutics
Resverlogix Corp.
Eisai Co., Ltd.
Novartis AG
Cipla Inc.
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd
Dr. Reddy’s Laboratories Ltd
Johnson & Johnson Services, Inc.

Key Segments Profiled in the Vascular Dementia Treatment Industry Analysis:

By Type:

Pipeline Development Activities
Reimbursement Scenario in Vascular Dementia (VaD)
Multi-infarct dementia
Binswanger disease
Vascular dementia from a strategic single-infarct
BAC: Charsire Biotechnology Corp
PNA1: ProNeurogen Therapeutics

By Treatment:

Drug class
Route of administration
Distribution channel

By End User:

Hospitals and Clinics
Rehabilitation Centers
Others

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Opioid Use Disorder Treatment Market Set to Reach USD 8.4 Billion by 2033, Expanding at a CAGR of 10.5%: FMI Study

The global opioid use disorder treatment market is poised for significant growth, with an expected market size of USD 3.07 billion in 2023 and a projected valuation of USD 8.4 billion by 2033. This growth reflects an impressive compound annual growth rate (CAGR) of 10.5% during the forecast period. As the opioid abuse crisis continues to escalate, the market for OUD treatments is gaining momentum, driven by increased awareness, research advancements, and strategic collaborations.

Raising Awareness to Combat the Opioid Crisis:

One of the key factors propelling the market expansion is the growing awareness about the dangers of opioid abuse and the importance of seeking treatment. Drug abuse treatment providers and manufacturers are increasingly focusing on educating the public, including drug store owners, about the severe effects of drug misuse. Media campaigns through television, newspapers, brochures, and other platforms have proven effective in curbing opioid abuse, broadening the reach of treatment options and directly contributing to the market’s growth.

Strategic Partnerships Fuel Market Growth:

Collaborations between industry leaders and organizations have further bolstered the treatment landscape. Notably, GlaxoSmithKline partnered with 2morrow Inc. in 2016 to offer SmartQuit app users nicotine patches as part of a comprehensive smoking cessation program. Similarly, in 2013, the company teamed up with Amneal Pharmaceuticals to distribute Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets, a generic version of Suboxone, to addiction treatment centers. Such partnerships are expected to play a critical role in long-term market expansion.

Research & Development Driving Innovation:

As the opioid addiction crisis continues to worsen, the need for integrated research and development into addiction treatment and recovery has grown. Research efforts in addressing opioid use disorder have surged, with stakeholders focusing on translating these findings into real-world care solutions. This ongoing R&D will be a key driver of market growth in the coming years, with the development of new treatment options that better address the needs of individuals struggling with opioid addiction.

Key Market Drivers:

Several factors are fueling the growth of the OUD treatment market, including the rising prevalence of chronic pain-related diseases such as cancer, arthritis, lower back pain, fibromyalgia, and post-surgical pain. Additionally, there is increasing demand for extended-release opioid formulations over immediate-release options, as well as a growing focus on abuse-deterrent formulations (ADF) by generic manufacturers.

Government Initiatives and Mergers & Acquisitions:

In countries like the United Kingdom, public and privately funded programs by the National Health Service (NHS) are playing a vital role in the treatment of opioid use disorder. Furthermore, strategic mergers and acquisitions are enhancing the market’s reach and capabilities. For instance, Acadia Healthcare’s acquisition of Priory Group in December 2015 allowed the company to expand its behavioral care services and geographic presence, further strengthening the OUD treatment market.

Challenges and Outlook:

Despite the positive growth trajectory, challenges remain, notably the rising costs associated with advanced treatment processes. While significant investments in new, medically advanced treatments are essential to boosting recovery rates, the resulting increase in treatment costs poses a challenge to broader market accessibility. Nonetheless, the expanding focus on opioid use disorder treatment, coupled with strategic industry collaborations, is set to overcome these hurdles, ensuring continued market growth.

In conclusion, the global opioid use disorder treatment market is on a robust growth path, supported by rising awareness, strategic collaborations, increasing R&D investment, and governmental initiatives aimed at combating the opioid epidemic. As these factors continue to evolve, the market is expected to witness significant expansion, reaching new heights by 2033.

Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!

Key Takeaways:

North America is expected to dominate the industry while reaching market share of around 48% by the end of the forecast period.
The market in East Asia is projected to reflect fastest CAGR of 8.8% during the projected timeline.
By drug class, Buprenorphine is projected to account for 81.4% market share by end of the forecast period.
Hospitals are expected to dominate the market by distribution channel, with a market share of 35% by 2033.

“Rising collaborations and mergers between companies, increasing research and development activities and adoption of technological advanced techniques for treating Opioid disorder will drive the industry’s growth,” comments an FMI analyst

Competitive Landscape:

The Opioid use disorder treatment Market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of opioid use disorder. This is expected to propel Opioid use disorder treatment market. The major players in the market are: Trevena, Opiate Pharmaceutical, Aphios, Kyowa kirin, Gamida-Cell, Novartis, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., BioDelivery Sciences International, Inc.

Some recent developments in the market are:

In January 2022, Trevena, Inc. declared that China’s National Medical Products Administration (NMPA) has accepted the submission of a New Drug Application (NDA) for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the FDA for use in adults for managing acute pain severe enough to require an intravenous opioid analgesic.
In October 2021, Esteve Pharmaceuticals received authorisation from the United States Food and Drug Administration (FDA) for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is extreme enough to require an opioid analgesic.
In January 2020, Titan Pharmaceuticals, Inc. made a revelation that they had entered into an agreement with AllianceRx Walgreens Prime for the expansion of accessibility of patients for Titan’s opioid use disorder implant branded as “Probuphine implant”.

Key Segments Profiled in the Opioid Use Disorder Treatment Market Survey:

By Drug Type:

Romiplostim
Omidubicel
Nalmefene
Buprenorfine
Methadone
Naltrexone

By Route of Administration:

Oral
Parenteral

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global One-Step RT-qPCR Kits Market Poised for Robust Growth, Projected to Reach USD 180.0 Million by 2034

The global one-step RT-qPCR kits market is projected to grow significantly, reaching an estimated value of USD 111.1 million in 2024. The market is anticipated to witness a steady compound annual growth rate (CAGR) of 4.9%, with revenues expected to soar to USD 180.0 million by 2034.

The COVID-19 pandemic underscored the critical need for rapid and reliable diagnostic solutions, driving the demand for one-step RT-qPCR kits, widely recognized for their efficacy in detecting viral infections. This surge in demand during the public health emergency has had a lasting impact on the market, as the kits are now seen as an essential tool for detecting a wide range of viral pathogens.

Advancements in molecular biology and the continuous development of more efficient reagents, such as TaqMan Real-time PCR assays, have further fueled market growth. These innovations have not only enhanced the accuracy of diagnostic tests but also contributed to the broader acceptance and adoption of one-step RT-qPCR kits.

Additionally, the increasing prevalence of viral infections beyond COVID-19, including seasonal viruses, has led to a greater demand for reliable diagnostic solutions. The ongoing rise in research and development efforts within the scientific community has also contributed to a surge in the use of one-step RT-qPCR kits in research settings.

As the market continues to expand, the demand for one-step RT-qPCR kits remains strong, driven by both the need for more accessible diagnostic solutions and the ongoing advancement of molecular diagnostic technology. This growth trajectory highlights the growing importance of these kits in both clinical and research applications, ensuring they remain a key component of global healthcare infrastructure.

Key Takeaways:

The global one-step RT-qPCR kits market is expected to reach USD 111.1 million in 2024 and grow at a CAGR of 4.9% from 2024 to 2034, reaching an estimated USD 180.0 million by 2034.
Key regional growth trends include:
- Canada: Projected to experience a 3.7% Value CAGR between 2024 and 2034.
- Germany: Expected to see a 5.0% Value CAGR during the same period.
- France: Anticipated to have a 4.8% Value CAGR.
- Italy: Estimated to grow at a 4.6% Value CAGR.
- China: Expected to witness a 5.3% Value CAGR, reflecting strong demand.
- India: Projected to lead with a significant 7.5% Value CAGR.
- Japan: Estimated to grow at a robust 5.9% Value CAGR.

These projections highlight strong regional growth, with emerging markets like India and China showing significant potential in driving market expansion.

Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!

Competitive Landscape of the One Step RT-qPCR Kits Industry:

Key players in the market are strategically acquiring smaller, emerging companies to capitalize on their technological expertise, thereby enhancing their product portfolios and gaining a competitive edge. The surge in demand for rapid diagnostic kits during the Covid-19 pandemic prompted many companies to launch new diagnostic solutions, seizing the opportunity to meet market needs and expand their reach.

Another critical strategy employed by market leaders is securing product approvals across multiple countries, which helps diversify their revenue streams and strengthen their global presence.

Recent Industry Developments in the One Step RT-qPCR Kits Market

In July 2023, Fortis Life Sciences, LLC expanded its capabilities by acquiring Toronto-based International Point of Care, Inc. (IPOC), a leader in the development and manufacture of diagnostic components such as lyophilized reagents and recombinant proteins.

In August 2021, QIAGEN N.V. reached a significant milestone, having processed over three billion biological samples with its consumable kits. This achievement emphasizes QIAGEN’s leadership in providing essential tools for molecular laboratories in research, disease management, and forensic applications, further cementing the company’s commitment to advancing scientific discovery and improving global health outcomes.

Key Players of the One Step RT-qPCR Kits Industry:

Thermo Fisher Scientific Inc.
QIAGEN
Takara Bio Inc.
Bio-Rad Laboratories, Inc.
Promega Corporation
New England Biolabs
Fortis Life Sciences
Quantabio
BIO-HELIX
MP Biomedicals
Avantor, Inc.
Intact Genomics, Inc.
Solis BioDyne
Applied Biological Materials Inc.

One Step RT-qPCR Kits Market Segmentation

By Reaction:

In terms of reaction, the industry is segmented into 25 Rxn one step RT-qPCR kits, 50 Rxn one step RT-qPCR kits, 100 Rxn one step RT-qPCR kits, 200 Rxn one step RT-qPCR kits, 400 Rxn one step RT-qPCR kits, 500 Rxn one step RT-qPCR kits, 1000 Rxn one step RT-qPCR kits, and above 1000 Rxn one step RT-qPCR kits.

By Application:

In terms of application, the industry is bifurcated into chickenpox immunization and herpes zoster immunization.

By Detection:

In terms of end users, the industry is segregated into hospitals, clinics, and others.

By End User:

In terms of end users, the industry is segregated into hospitals, clinics, and others.

By Region:

Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, the Middle East, and Africa have been covered in the report.

About Future Market Insights (FMI)

Contact Us:

Global Canine Cancer Screening Market Set to Soar: Projected to Reach USD 2,087.9 Million by 2034 rise at a CAGR of 4.1%

The global canine cancer screening market is poised for significant growth over the next decade, reflecting a surge in demand for innovative and early detection solutions for canine health. According to recent market projections, the market is estimated to be worth USD 1,397.0 million in 2024 and is expected to reach an impressive USD 2,087.9 million by 2034, driven by a compound annual growth rate (CAGR) of 4.1% between 2024 and 2034.

In 2023, the market generated USD 1,342.0 million in revenue, underscoring a consistent upward trend. This growth is attributed to increasing pet ownership, heightened awareness of canine cancer, and advancements in diagnostic technologies that enable early and accurate detection.

Key Market Drivers:

Rising Awareness of Canine Health: Pet owners are becoming increasingly proactive about preventative care, leading to greater adoption of cancer screening solutions.
Advancements in Veterinary Diagnostics: Innovations such as liquid biopsy and non-invasive screening methods are enhancing detection capabilities and fueling market growth.
Expanding Pet Insurance Coverage: Comprehensive insurance plans for pets now often include cancer diagnostics, making screening more accessible.

Opportunities Ahead:

The growing emphasis on early detection and treatment offers significant opportunities for companies to develop advanced diagnostic tools tailored to diverse breeds and age groups. Additionally, collaborations between veterinary clinics, diagnostic labs, and pharmaceutical companies are expected to drive innovation and improve market penetration.

As the global pet care industry continues to evolve, the canine cancer screening market is set to play a pivotal role in safeguarding the health and longevity of dogs. Companies operating in this space are well-positioned to capitalize on the growing demand, further bolstered by supportive regulatory frameworks and technological advancements.

Key Takeaways from the Market Study

By test, the liquid biopsy (blood-based tests) holds a lucrative market share value of 7%. Liquid biopsy, especially blood-based tests, has gained the highest share by test type in the canine cancer screening market owing to a number of advantages over other conventional methods of diagnosis. These diagnostic tests are non-invasive, hence requiring only a blood sample, thereby decreasing stress and discomfort for the animal.
By technology, the next generation sequencing holds a 4% market value share in 2024. Therefore, NGS has emerged as the dominant technology in the canine cancer therapeutics market, which has fundamentally altered the way in which cancer is diagnosed and treated in dogs. NGS gives full genomic detail, allowing the identification of the exact genetic mutation or changes that may underlie cancer in dogs.
K. emerges as the primary region, with an expected CAGR of 4.4% from 2024 to 2034, The highly developed veterinary healthcare infrastructure in the country, with a subsequent network of state-of-the-art veterinary clinics and diagnostic laboratories, is notably responsible for this. The facilities are fully equipped with state-of-the-art technologies such as next-generation sequencing and liquid biopsy critical to the next generation, early detection, and diagnosis of cancer cases in canines. “The growing awareness among pet owners about the importance of regular health check-ups and early cancer detection is also propelling market growth.” says an analyst of Future Market Insights.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!

Market Competition:

Many companies strategize to capture competitors or other companies that generate less revenue. Market players are spending high amounts on research and development for new products to expand their market share. For instance,

In December 2023, Salarius Pharmaceuticals, Inca clinical-stage biopharmaceutical company and VolitionRx Limited a multinational epigenetics company, announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology.
In June 2022, PetDx® an liquid Biopsy company for Pets™ and Antech® Diagnostics jointly announced that they have collaborated to make OncoK9®, the pioneering multi-cancer early detection (MCED) test for dogs, available to all Antech customers across North America.

Key Players of Canine Cancer Screening Market:

IDEXX
Mars Pedtcare
Zoetis
PetDx
Molecular Diagnostics (MDxHealth)
Biomérieux SA
OncoK9
Antech Diagnostics
VolitionRx Limited
Oncotect
Heska Corporation

Key Segments of Canine Cancer Screening Market

By Test Type:

In terms of test type, the industry is segregated into liquid biopsy (blood-based tests), tissue biopsy, genomic testing and biomarker tests.

By Technology:

In terms of technology, the industry is segregated into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), flow cytometry and in situ hybridization.

By Cancer:

In terms of cancer, the industry is segregated into lymphoma, mast cell tumors, osteosarcoma and hemangiosarcoma.

By End User:

In terms of end user, the industry is segregated into veterinary clinics, veterinary hospitals, diagnostic laboratories, academic & research institutes, pet owners (home-based testing kits).

By Region:

Key countries of North America, Latin America, Western Europe, Eastern, South Asia, East Asia and Middle East and Africa (MEA) have been covered in the report.

About Future Market Insights (FMI)

Contact Us:

Global Cytogenetic Systems Market Set for Exceptional Growth, Projected to Reach USD 5,327.8 Million by 2032

The global cytogenetic systems market is on track for a remarkable surge, with expectations to reach an impressive valuation of USD 5,327.8 Million by 2032. This represents a significant leap from its estimated worth of USD 1,688.5 Million in 2022, reflecting an extraordinary growth trajectory driven by a robust Compound Annual Growth Rate (CAGR) of 11.0%.

This phenomenal growth is underpinned by several pivotal factors that are advancing genetic research and diagnostics. The rising incidence of genetic disorders and cancer worldwide is driving an increased demand for sophisticated cytogenetic systems. As these conditions become more prevalent, the need for accurate diagnosis, prognosis, and personalized treatment strategies becomes more critical.

Key Drivers of Growth:

Advancements in Genetic Research: Rapid progress in genetic research is a key driver of the unprecedented growth in the cytogenetic systems industry. Cutting-edge technologies and methodologies are enhancing our understanding of genetic complexities, paving the way for more precise diagnostic solutions.
Rising Incidence of Genetic Disorders and Cancer: The surge in demand is a direct response to the growing prevalence of genetic disorders and cancer worldwide. Cytogenetic systems play a pivotal role in enabling healthcare professionals to accurately diagnose and prognosticate these conditions, facilitating tailored treatment approaches for better patient outcomes.
Personalized Treatment Strategies: Cytogenetic systems contribute significantly to the development of personalized treatment strategies. As the medical field embraces more individualized approaches, these systems become integral tools for tailoring interventions to the unique genetic makeup of each patient.

Industry Projections and Impact:

The projected valuation of USD 5.3 billion by 2032 underscores the industry’s trajectory towards a robust future. This growth not only signifies the increasing adoption of cytogenetic systems but also reflects a global commitment to advancing healthcare through innovative diagnostic solutions.

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!

Cytogenetic systems industry: Drivers and Restraints

The key contributor to the growth of global Cytogenetic systems industry is rising demand of early diagnosis of severe life threatening diseases such as cancer and diagnosis of disorders due to chromosomal anomalies in developing embryos. Moreover, expansion of geriatric population pool, rising exposure to dangerous chemicals and ultraviolet rays, increase in numbers of people adopting bad habits such as smoking and drinking and the sedentary lifestyle is fuelling the market growth.

There are some factors which may slow down the market growth rate including technical limitations and complexities associated with the equipment, lack of awareness about advanced technological methodologies especially in low and middle income countries and high cost of sophisticated devices.

Cytogenetic systems industry: Key Players

Some of the players in the global Cytogenetic systems industry include ADS Biotec Inc., Genial Genetics, Laboratory Imaging s.r.o., MetaSystems, Agilent Technologies, Cytocell Ltd, Leica Biosystems Nussloch GmbH, Applied Spectral Imaging, Irvine Scientific, PerkinElmer Inc., Bio-Rad Laboratories, Inc. and Abbott Laboratories.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Cytogenetic systems industry: Segmentation

Global Cytogenetic systems industry has been segmented on the basis of technologies, applications, end users and region.

Based on technologies, the global Cytogenetic systems industry is segmented into:

Flow cytometry
Fluorescence In Situ Hybridization (FISH)
Multiplex- Fluorescence In Situ Hybridization (M-FISH)
Comparative Genomic Hybridization (CGH)

Based on applications, the global cytogenetic systems industry is segmented into:

Genetic Disorders
Neoplastic Diseases
Personalized Medicine
Others

Based on end users, the global Cytogenetic systems industry is segmented into:

Hospitals
Clinics
Diagnostic Laboratory Centers
Research Institutes

About Future Market Insights (FMI)

Contact Us: